EXEL

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Exelixis Inc

NASDAQ | EXEL

40.44

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 17, 2025)

$10.89B

Market Cap

19.44

P/E Ratio

2.08

EPS

$49.62

52 Week High

$25.17

52 Week Low

HEALTHCARE

Sector

EXEL Chart

Recent Chart
Price Action

EXEL Technicals

Tags:

EXEL Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2.1B
Total Revenue $2.2B
Cost Of Revenue $76M
Costof Goods And Services Sold $76M
Operating Income $605M
Selling General And Administrative $492M
Research And Development $910M
Operating Expenses $1.5B
Investment Income Net -
Net Interest Income $77M
Interest Income $77M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $29M
Income Before Tax $682M
Income Tax Expense $160M
Interest And Debt Expense -
Net Income From Continuing Operations $521M
Comprehensive Income Net Of Tax -
Ebit $690M
Ebitda $719M
Net Income $521M

Revenue & Profitability

Earnings Performance

EXEL Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $2.9B
Total Current Assets $1.5B
Cash And Cash Equivalents At Carrying Value $140M
Cash And Short Term Investments $140M
Inventory $22M
Current Net Receivables $280M
Total Non Current Assets $1.5B
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill $64M
Investments -
Long Term Investments $637M
Short Term Investments $971M
Other Current Assets $54M
Other Non Current Assets -
Total Liabilities $703M
Total Current Liabilities $404M
Current Accounts Payable $38M
Deferred Revenue -
Current Debt -
Short Term Debt $25M
Total Non Current Liabilities $300M
Capital Lease Obligations $191M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $216M
Other Current Liabilities $338M
Other Non Current Liabilities $109M
Total Shareholder Equity $2.2B
Treasury Stock -
Retained Earnings -$99M
Common Stock $282K
Common Stock Shares Outstanding $296M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $700M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $29M
Capital Expenditures $66M
Change In Receivables -
Change In Inventory $5.5M
Profit Loss -
Cashflow From Investment -$117M
Cashflow From Financing -$629M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$652M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $521M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2.1B
Total Revenue $2.2B
Cost Of Revenue $76M
Costof Goods And Services Sold $76M
Operating Income $605M
Selling General And Administrative $492M
Research And Development $910M
Operating Expenses $1.5B
Investment Income Net -
Net Interest Income $77M
Interest Income $77M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $29M
Income Before Tax $682M
Income Tax Expense $160M
Interest And Debt Expense -
Net Income From Continuing Operations $521M
Comprehensive Income Net Of Tax -
Ebit $690M
Ebitda $719M
Net Income $521M

EXEL News

EXEL Profile

Exelixis Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Exelixis, Inc. is a leading biotechnology firm dedicated to advancing innovative therapies for the treatment of cancer, primarily within the United States. Headquartered in Alameda, California, the company specializes in the discovery and development of novel cancer treatments, with a robust pipeline that underscores its commitment to improving patient outcomes. Exelixis' strategic focus on oncology harnesses cutting-edge research and development to deliver transformative solutions in a competitive landscape, positioning it as a key player in the biopharmaceutical industry.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
NIO
+6.05%
$7.44
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
AAL
+0.56%
$12.48
TSLA
+1.00%
$425.86
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
RGTI
+9.94%
$21.99
SOFI
-1.02%
$27.14
TPIC
-45.91%
$0.12
ADAP
-1.22%
$0.08
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
BBD
+3.11%
$3.31
BMNR
+2.03%
$57.07
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
KDLY
-4.66%
$1.43
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
IONQ
+5.10%
$65.44
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
RIOT
+0.57%
$17.62
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
INFY
+3.63%
$17.68
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
GPUS
+6.65%
$0.41
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RXRX
-2.68%
$4.71
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
NIO
+6.05%
$7.44
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
AAL
+0.56%
$12.48
TSLA
+1.00%
$425.86
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
RGTI
+9.94%
$21.99
SOFI
-1.02%
$27.14
TPIC
-45.91%
$0.12
ADAP
-1.22%
$0.08
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
BBD
+3.11%
$3.31
BMNR
+2.03%
$57.07
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
KDLY
-4.66%
$1.43
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
IONQ
+5.10%
$65.44
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
RIOT
+0.57%
$17.62
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
INFY
+3.63%
$17.68
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
GPUS
+6.65%
$0.41
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RXRX
-2.68%
$4.71
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.